Myriad Genetics Inc

Research Myriad Genetics Inc (MYGN) on Bullrun: market cap USD 304.96M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 304.96M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 824.50M-USD 366.00M-USD 25.60M69.9%-3.95USD 149.60MUSD 119.90MUSD 368.00M
FY2024USD 837.60M-USD 127.00M-USD 38.40M69.9%-1.41USD 102.40MUSD 39.60MUSD 701.10M
FY2023USD 753.20M-USD 263.00M-USD 184.20M68.6%-3.18USD 132.10MUSD 38.50MUSD 783.20M
FY2022USD 678.40M-USD 112.00M-USD 151.60M70.2%-1.39USD 56.90MUSD 0USD 885.80M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 304.96Mn/an/an/a
20252025-12-31USD 575.03Mn/an/an/a
20242024-12-31USD 1.25Bn/an/an/a
20232023-12-29USD 1.72Bn/an/an/a
20222022-12-30USD 1.18Bn/an/an/a
20212021-12-31USD 2.21Bn/an/an/a

About Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Myriad Genetics Inc's market cap?

Myriad Genetics Inc's market capitalization is USD 304.96M.

What does Myriad Genetics Inc do?

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.